101 related articles for article (PubMed ID: 38775809)
1. Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance.
Sui Y; Wang T; Mei Y; Zhu Y; Jiang W; Shen J; Yan S; Lu W; Zhao K; Mo J; Wang C; Tang Y
Cancer Res; 2024 May; ():. PubMed ID: 38775809
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
Mo J; Liu F; Sun X; Huang H; Tan K; Zhao X; Li R; Jiang W; Sui Y; Chen X; Shen K; Zhang L; Ma J; Zhao K; Tang Y
Cancer Res; 2021 Jun; 81(11):3105-3120. PubMed ID: 33853831
[TBL] [Abstract][Full Text] [Related]
4. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
5. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
6. Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog-GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition.
Peer E; Aichberger SK; Vilotic F; Gruber W; Parigger T; Grund-Gröschke S; Elmer DP; Rathje F; Ramspacher A; Zaja M; Michel S; Hamm S; Aberger F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439381
[TBL] [Abstract][Full Text] [Related]
7. ABT-737 suppresses aberrant Hedgehog pathway and overcomes resistance to smoothened antagonists by blocking Gli.
Huang W; Liu H; Tan W; Wang J
Med Oncol; 2022 Sep; 39(12):188. PubMed ID: 36071246
[TBL] [Abstract][Full Text] [Related]
8. The hedgehog pathway in hematopoiesis and hematological malignancy.
Lemos T; Merchant A
Front Oncol; 2022; 12():960943. PubMed ID: 36091167
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog pathway and smoothened inhibitors in cancer therapies.
Chahal KK; Parle M; Abagyan R
Anticancer Drugs; 2018 Jun; 29(5):387-401. PubMed ID: 29537987
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Hedgehog pathway with novel Gli1 hydrophobic tagging degraders.
Li X; Sun R; Wu H; Zheng C; Long YQ
Bioorg Chem; 2023 Sep; 138():106649. PubMed ID: 37307715
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
Pietrobono S; Stecca B
Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog inhibitors: a patent review (2013 - present).
Xin M
Expert Opin Ther Pat; 2015 May; 25(5):549-65. PubMed ID: 25726713
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
14. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
15. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.
Zhao J; Quan H; Xie C; Lou L
Pharmacol Res Perspect; 2014 Jun; 2(3):e00043. PubMed ID: 25505589
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.
Wu A; Turner KA; Woolfson A; Jiang X
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986819
[TBL] [Abstract][Full Text] [Related]
17. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
Cell Chem Biol; 2024 Feb; ():. PubMed ID: 38442710
[TBL] [Abstract][Full Text] [Related]
18. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog pathway as a drug target: Smoothened inhibitors in development.
Lin TL; Matsui W
Onco Targets Ther; 2012; 5():47-58. PubMed ID: 22500124
[TBL] [Abstract][Full Text] [Related]
20. The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Bhateja P; Cherian M; Majumder S; Ramaswamy B
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31394751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
